- The single dose pharmacokinetics of ribavirin in subjects with chronic liver diseaseP Glue
Schering Plough Research Institute, Kenilworth, NJ 07033, USA
Br J Clin Pharmacol 49:417-21. 2000..Additionally this study assessed the safety and tolerability of ribavirin in this population...
- A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy GroupP Glue
Schering Plough Research Institute, Kenilworth, NJ
Hepatology 32:647-53. 2000..Combined PEG-Intron/ribavirin showed dose-related synergistic anti-HCV effects, which were numerically superior to those obtained with PEG-Intron monotherapy...
- Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis CJ F Jen
Department of Statistics, Schering Plough Research Institute, Kenilworth, NJ 007033, USA
Clin Pharmacol Ther 69:407-21. 2001..Possible relationships between pharmacokinetic and pharmacodynamic variables were investigated...
- Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairmentS K Gupta
Departments of Drug Metabolism Pharmacokinetics and Clinical Pharmacology, Merck Research Lab, Kenilworth, NJ, USA
Drug Discov Ther 7:158-63. 2013..The pharmacokinetics of ribavirin were substantially altered in subjects with stable chronic renal impairment, possibly reflecting changes in ribavirin metabolism associated with renal impairment. ..